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Abstract
Alterations to branched-chain keto acid (BCKA) oxidation have been implicated in a wide variety 
of human diseases, ranging from diabetes to cancer. Although global shifts in BCKA metabolism
—evident by gene transcription, metabolite profiling, and in vivo flux analyses have been 
documented across various pathological conditions, the underlying biochemical mechanism(s) 
within the mitochondrion remain largely unknown. In vitro experiments using isolated 
mitochondria represent a powerful biochemical tool for elucidating the role of the mitochondrion 
in driving disease. Such analyses have routinely been utilized across disciplines to shed valuable 
insight into mitochondrial-linked pathologies. That said, few studies have attempted to model in 
vitro BCKA oxidation in isolated organelles. The impetus for the present study stemmed from the 
knowledge that complete oxidation of each of the three BCKAs involves a reaction dependent 
upon bicarbonate and ATP, both of which are not typically included in respiration experiments. 
Based on this, it was hypothesized that the inclusion of exogenous bicarbonate and stimulation of 
respiration using physiological shifts in ATP-free energy, rather than excess ADP, would allow for 
maximal BCKA-supported respiratory flux in isolated mitochondria. This hypothesis was 
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confirmed in mitochondria from several mouse tissues, including heart, liver and skeletal muscle. 
What follows is a thorough characterization and validation of a novel biochemical tool for 
investigating BCKA metabolism in isolated mitochondria.
Introduction
Leucine, isoleucine, and valine, collectively referred to as ‘branched-chain amino acids’ 
(BCAAs), are essential amino acids with vital roles in cellular metabolism. One such role 
involves energy production through the oxidation of the BCAA carbon skeletons within the 
mitochondrion [1]. These metabolites include ketoisocaproate (KIC), ketomethylvalerate 
(KMV), and ketoisovalerate (KIV), known generally as the ‘branched-chain keto acids’ 
(BCKAs). The importance of BCKA oxidation in the periphery is perhaps best demonstrated 
by the pathophysiological consequences linked to maple syrup urine disease (MSUD), 
caused by inborn errors within the BCKA dehydrogenase complex (BCKDH) genes [2]. In 
addition to MSUD, interest in BCKA metabolism has dramatically expanded in recent years 
with the discovery that limitations in BCKA catabolism underlie several other human 
diseases. To date, dysfunctional BCKA oxidation has been demonstrated in diabetes [3,4], 
hepatocellular carcinoma [5], heart failure [6], and ischemia–reperfusion injury [7]. Apart 
from BCKDH inborn errors (i.e. MSUD), the precise biochemical lesion responsible for 
lower overall BCKA catabolic flux in these diseases remains unclear.
Elucidating the mechanism(s) driving stress-induced shifts in BCKA metabolism requires 
experimental methodologies capable of isolating the BCKA pathway and interrogating 
individual enzyme flux. One such tool involves in vitro analysis of isolated mitochondria. 
Indeed, numerous examples exist in which bioenergetic conclusions deduced from in vitro 
mitochondrial profiling have been paramount in the discovery, support or validation of 
various mitochondrial pathologies [8–12]. That said, only a handful of studies have 
attempted to model BCKA oxidation in isolated organelles [6,7,13–15]. In every case, 
evidence of respiratory control (i.e. a change in mitochondrial respiration in response to free 
ADP) specifically mediated by exogenous BCKAs has not been demonstrated, possibly due 
to insufficient optimization of the experimental conditions.
Following transamination, all BCKAs undergo decarboxylation via mitochondrial matrix-
localized BCKDH. Decarboxylation by BCKDH represents the first committed step of 
BCKA oxidation and produces BCKA-specific short-chain acyl-CoAs (KIC > isovaleryl-
CoA: KMV > methylbutyryl-CoA:KIV > isobutyryl-CoA). Each acyl-CoA is then processed 
via a series of keto acid-specific steps ultimately leading to the production of either acetyl-
CoA and/or succinyl-CoA (Figure 1). Of note, BCKA catabolism is distinct from pyruvate 
or fatty acyl-CoA metabolism in that complete oxidation of each BCKA requires both 
bicarbonate and ATP, neither of which are traditionally present in isolated mitochondria 
experiments. The natural sequitur to this issue formed the guiding hypothesis herein: 
inclusion of bicarbonate and ATP-free energy would allow for appreciable BCKA-supported 
oxygen consumption. To test this hypothesis, a recently described mitochondrial diagnostics 
workflow was employed which leverages the creatine kinase (CK) energetic clamp to allow 
respiration measurements across a physiological span of ATP/ADP ratios (i.e. ATP-free 
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energy of hydrolysis; ΔGATP) [16]. Using this methodology in the presence of exogenous 
bicarbonate, several novel aspects of mitochondrial BCKA metabolism were unveiled, 
highlighted by tissue-specific (e.g. heart, liver, skeletal muscle) differences in pathway 
responsivity to ATP-free energy. Specifically, in the absence of post-translation control (i.e. 
BCKDH phosphorylation) [17], BCKA oxidation in muscle mitochondria was found to be 
directly responsive to ATP-free energy, rather than the adenylate pool per se. The 
methodological framework outlined and validated herein serves as a blueprint for a powerful 
new biochemical tool for investigating BCKA oxidation. The assays outlined will likely be 




All animal studies were approved by the East Carolina University Institutional Animal Care 
and Use Committee. All experiments involving laboratory mice were carried out at the East 
Carolina Diabetes and Obesity Institute. C57BL/6J male mice (8 weeks old) were purchased 
from Jackson Laboratory (strain #000664). Unless otherwise stated, all experiments were 
completed using 12- to 16-week-old mice following a 2-h fast. All mice were housed in a 
temperature (22°C) and light-controlled (12 h light/12 h dark) room and given free access to 
food and water. Unless otherwise stated, mice were anesthetized with isoflurane, and the 
following tissues were removed for mitochondrial isolation and functional analysis: skeletal 
muscle (gastrocnemius, plantaris, soleus, and quadriceps), heart (complete left and right 
ventricles), and liver (whole). For experiments designed to inhibit the branched-chain keto 
acid dehydrogenase kinase (BCKDK) in vivo, C57BL/6J mice were fasted for 4 h then 
injected with either 3-chloro-benzo[b]thiophene-2-carboxylic acid (BT2; 40 mg/kg) [18,19] 
or vehicle control (DMSO). Inhibition of BCKDH kinase via BT2 has been shown to 
activate BCKA oxidation in vivo by promoting dephosphorylation of BCKDH [18,19]. 
Average injection volumes per mouse were ~25 μl. Tissues were harvested 1-h post-injection 
and heart mitochondria were isolated as described below.
Chemicals and reagents
Unless otherwise stated, all chemicals were purchased from Millipore-Sigma, including 
dipotassium phosphocreatine (Cat#237911), KIC (Cat#K0629), KMV (Cat#198978), and 
KIV (Cat#198978). Potassium NADP+ (Cat#AK671068) and ATP (Cat#AK54737) were 
purchased from Ark-Pharm. Potassium pyruvate was purchased from Combi-Blocks 
(QA-1116). Amplex UltraRed (AUR) and tetramethylrhodamine methyl ester (TMRM) were 
purchased from Thermo Fisher Scientific. The following experimental buffers were used for 
all assays: Buffer A—50 mM MOPS supplemented with KCl (100 mM), EGTA (1 mM), 
and MgSO4 (5 mM), pH 7.1; Buffer B—Buffer A, supplemented with 0.2% BSA, pH 7.1; 
Buffer C—105 mM MES potassium salt supplemented with KCl (30 mM), EGTA (1 mM), 
KH2PO4 (10 mM), MgCl2 (5 mM), and BSA (0.25%), pH 7.2. Buffer D—HEPES (20 mM), 
KCl (100 mM), KH2PO4 (2.5 mM), MgCl2 (2.5 mM), glycerol (1%), pH 8.0.
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Differential centrifugation was used to isolate mitochondria from heart, liver, and skeletal 
muscle. Buffers A and B were utilized in all isolations. Heart, liver, and skeletal muscle were 
dissected and placed in ice-cold Buffer B. Tissues were then minced, resuspended in 10 ml 
of Buffer B and homogenized for ~10–15 passes via a Teflon pestle and borosilicate glass 
vessel. The homogenate was transferred to a 15 ml tube, the volume was brought to 12 ml, 
and samples were centrifuged at 600×g for 10 min at 4°C. The supernatants were poured 
through two layers of gauze and spun at 10 000×g for 10 min at 4°C. Mitochondrial pellets 
were washed in 1.4 ml of Buffer A and spun at 10 000×g for 10 min at 4°C. The resulting 
pellets were resuspended in Buffer A. Protein content was determined using the Pierce BCA 
assay.
Mitochondrial respiratory control using the creatine kinase clamp
High-resolution O2 consumption measurements were conducted using the Oroboros 
Oxygraph-2K (Oroboros Instruments). All experiments were carried out at 37°C in a 2 ml 
reaction volume with continuous stirring. Steady-state oxygen consumption rates (JO2) were 
determined within individual experiments using a modified version of the CK energetic 
clamp technique [16,20,21]. In this assay, the free energy of ATP hydrolysis (ΔG′ATP, 
depicted throughout the manuscript as ΔGATP) can be calculated based on known amounts of 
creatine (Cr), phosphocreatine (PCR) and ATP in combination with excess amounts of CK 
and the equilibrium constant for the CK reaction (i.e. KCK). Calculation of ΔG′ATP was 
performed according to the following formula:
ΔGATP′ = ΔGATP
′ ∘ + RT ln
[Cr] Pi
[PCR] K′CK
where ΔG′°ATP is the standard apparent transformed Gibbs energy (under a specified pH, 
ionic strength, free magnesium, and pressure), R is the gas constant (8.3145 J/kmol), and T 
is the temperature in Kelvin (310.15). Given that experiments were performed via sequential 
additions of PCr, both the ΔG′°ATP and K′CK were determined at each titration step based 
on the changes in buffer ionic strength and free magnesium, as previously described [16]. 
Although not accounted for in the present study, the presence of mitochondrial CK within 
the inner mitochondrial membrane of heart mitochondria may have influenced the accuracy 
of the calculated ΔGATP [22]. Buffer for all assays was Buffer C, supplemented with ATP (5 
mM), Cr (5 mM), PCR (1 mM), and CK (20 U/ml). For all experiments, PCR final 
concentrations of 1, 6, 9, 15, 21, and 27 mM corresponded to ΔGATP of −12.94, −14.08, 
−14.34, −14.65, −14.84, and −14.99 kcal/mol. For reference, ΔGATP of −12.94 and −14.84 
kcal/mol correspond to ATP/ADP ratios of ~29.5 and ~554.6, respectively. Experiments 
designed to test the impact of bicarbonate utilized potassium bicarbonate (2 mM). For each 
experiment, isolated mitochondria were added to assay buffer, followed by the addition of 
respiratory substrates. A complete list of all substrate combinations and inhibitors used is 
provided in Supplementary Table S1. Following substrate additions, sequential additions of 
PCR were performed to manipulate ATP-free energy. For experiments designed to test the 
impact of BCKAs on JO2, a 1:1:1 mixture of BCKAs (1 mM each of KIC, KMV, KIV) was 
compared with NaCl (3 mM). The use of NaCl for control was required as all BCKAs were 
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provided as sodium salts. Either BCKAs or NaCl was added to mitochondria prior to the 
addition of each respiratory substrate.
Bicarbonate titrations
Experiments were performed in liver (0.1 mg/ml) and heart (0.05 mg/ml) mitochondria. For 
the hexokinase–ADP clamp, Buffer C was supplemented with Cr (5 mM), ADP (0.5 mM), 
glucose (5 mM), and hexokinase (HK; 1 U/ml). For the CK clamp, Buffer C was 
supplemented with Cr (5 mM), ATP (5 mM), PCR (21 mM), and CK (20 U/ml). The 
inclusion of PCR at 21 mM (i.e. ΔGATP of −14.84 kcal/mol) for the bicarbonate titrations 
was to ensure that ATP-free energy was not rate-limiting throughout the CK clamp 
experiment. Following the addition of buffer and mitochondria to the chambers, KIV was 
added and allowed to equilibrate. Potassium bicarbonate was then titrated in using sequential 
additions, resulting in concentrations of 0.1 mM, 0.2, 0.5, 1.0, 2.0, and 4.0 mM. Stable flux 
values were recorded at baseline and after each bicarbonate titration.
Mitochondrial membrane potential (ΔΨ) and NAD(P)H/NAD(P)+ redox
Fluorescent determination of ΔΨ and NAD(P)H/NAD(P)+ was carried out simultaneously 
via a QuantaMaster Spectrofluorometer (QM-400; Horiba Scientific) as previously described 
[16] with slight modifications. Determination of ΔΨ via TMRM was done by recording the 
fluorescence ratio of the following excitation/emission parameters [Ex:Em, (572:590)/
(551:590)]. NAD(P)H excitation/emission parameters were 350:450. All experiments were 
carried out at 37°C in a 0.2 ml reaction volume with continuous stirring. Buffer for all assays 
was Buffer C, supplemented with Cr (5 mM), PCR (1 mM), ATP (5 mM), CK (20 U/ml), 
TMRM (0.2 μM), and where indicated, bicarbonate (2 mM). For each assay, isolated 
mitochondria were added to the assay buffer, followed by the addition of respiratory 
substrates and then sequential PCR additions. At the end of the protocol, potassium cyanide 
(10 mM) was added to induce a state of 100% reduction within the NAD(P)H/NAD (P)+ 
couple, followed by alamethicin (0.03 mg/ml) to eliminate ΔΨ polarization and NAD(P)H 
reduction. The fluorescence (Ex:Em, 350:450) signal, as well as the 572/551 ratio described 
above, recorded in the presence of mitochondria plus alamethicin was subtracted from all 
other values during the assay (Supplementary Figure S1). Final ΔΨ values are presented as 
the alamethicin-mediated 572/551 ratio subtracted from the observed 572/551 ratio. Final 
NAD(P)H/NAD(P)+ redox data are presented as the fluorescence intensity (350:450) 
recorded minus that recorded in the presence of alamethicin.
H2O2 emission
Mitochondrial H2O2 emission was measured fluorometrically via the AUR/horseradish 
peroxidase (HRP) detection system (Ex:Em, 565:600) as described previously [16], with 
slight modifications. Fluorescence was monitored via a QuantaMaster Spectrofluorometer 
(Horiba Scientific). For each experiment, resorufin fluorescence was converted to picomoles 
H2O2 via an H2O2 standard curve generated under identical substrate conditions as 
employed for each protocol. All experiments were carried out at 37°C in a 0.2 ml reaction 
volume. Buffer for all assays was Buffer C, supplemented with Cr (5 mM), PCR (1 mM), 
CK (20 U/ml), AUR (10 μM), HRP (1 U/ml), superoxide dismutase (20 U/ml), and 
auranofin (AF; 0.1 μM). Auranofin at 0.1 μM has been demonstrated to be specific for 
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thioredoxin reductase inhibition [23,24]. At higher concentrations (~10 μM), auranofin 
inhibits glutathione peroxidase [24]. To begin, isolated mitochondria (0.1 mg/ml) were 
added to assay buffer, followed by the addition of respiratory substrates and then sequential 
PCR additions to 6 and 21 mM. A specific inhibitor of respiratory complex III (antimycin A; 
5 μM) was added at the conclusion of each protocol to serve as a positive control for JH2O2 
emission. The percentage of electron leak was calculated by dividing the rate of H2O2 
production by the corresponding O2 consumption rate measured under similar conditions 
and expressed as a percentage (% Leak = JH2O2/JO2). Of note, the JH2O2 rates used in the 
calculation were generated in the presence of auranofin; however, the corresponding JO2 
assays did not contain auranofin, as the inhibitor does not impact respiratory conductance 
[16].
JNADH and JNADPH production
All assays were performed using alamethicin-permeabilized (0.03 mg/ml) mitochondria 
suspended in Buffer A [25]. Rates of NADH and NADPH production were determined as 
described previously [16]. Buffer for the assays was Buffer C, supplemented with rotenone 
(0.005 mM) and NAD+ (2 mM) or NADP+ (2 mM). For experiments designed to assess 
JNADH from the pyruvate dehydrogenase complex (PDH), the α-ketoglutarate 
dehydrogenase complex (AKGDH), and the BCKDH, coenzyme A (0.1 mM) and thiamine 
pyrophosphate (0.3 mM) were included. Assay buffer (200 μl) was loaded into individual 
wells of a 96-well plate, followed by permeabilized mitochondria. The assay was initiated 
with the addition of enzymatic substrates. In the assay, NADH and NADPH were 
determined via autofluorescence (Ex:Em, 340:450). The following substrates were tested in 
parallel for each assay: pyruvate (5 mM) for PDH, AKG (10 mM) for AKGDH, KMV (5 
mM) for BCKDH, glutamate (10 mM) for glutamate dehydrogenase (GDH), malate (5 mM) 
for NAD-linked MDH and NADP-linked malic enzyme (ME), isocitrate (5 mM) for NAD-
linked IDH3 and NADP-linked IDH2. Data are presented as change in fluorescence (RFU 
[relative fluorescence unit]) per unit time normalized to the mitochondrial protein amount 
added. For experiments involving in vivo treatment with BT2, both BCKDH and PDH 
activity were determined under the same buffer conditions as described above; however, 
fluorescence measurements were made using a QuantaMaster Spectrofluorometer (QM-400; 
Horiba Scientific) with Ex:Em of 350:450.
Hydroxyacyl-CoA dehydrogenase (HADHA) activity
The assay was performed using alamethicin-permeabilized (0.03 mg/ml) mitochondria 
suspended in Buffer A. Buffer for the assay was Buffer D, supplemented with rotenone 
(0.005 mM) and NADH (0.2 mM). Assay buffer (200 μl) was loaded into individual wells of 
a 96-well plate, followed by permeabilized mitochondria. The assay was initiated with the 
addition of acetoacetyl-CoA (0.2 mM). The activity of hydroxyacyl-CoA dehydrogenase 
was determined via tracking the degradation in the NADH autofluorescence (Ex:Em, 
340:450) signal upon acetoacetyl-CoA addition. Data are presented as change in 
fluorescence (RFU) per unit time normalized to the mitochondrial protein amount added.
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Quantification and statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed using JMP® Pro 13 
(Version 13.2). Normality of all data was assessed using a Shapiro–Wilk W test. Normally 
distributed data were compared using either a paired (all in vitro experiments) or unpaired 
(BT2 treatment experiments) Student’s t-test. Non-normal data were compared using the 
Wilcoxon Signed Rank test. The level of significance was set at P < 0.05. Mitochondrial 
diagnostics results (Figure 5) were analyzed using a data analysis toolkit developed in 
Python. The toolkit was written using Python 2.7 and is published on the Python Package 
Index at https://pypi.org/project/kfwx/ (MacOS X and Windows). Figures were generated 
using GraphPad Prism (Version 8.0).
Results
BCKA oxidation in heart mitochondria requires both ATP and bicarbonate
To determine whether bicarbonate and ATP are required for BCKA oxidation, bioenergetic 
experiments were designed to assess mitochondrial respiration supported by saturating 
KMV (2 mM) in the presence and absence of potassium bicarbonate and increasing ATP-
free energies of hydrolysis. Manipulation of ΔGATP was made possible through the 
application of a recently described mitochondrial diagnostics assay platform [16] that 
leverages a modified version of the CK energetic clamp [20,21] to assess respiratory control 
across a physiological span of ATP-free energies (−12.94 to −14.84 kcal/mol). To begin, 
isolated heart mitochondria were energized with KMV in the absence and presence of 2 mM 
bicarbonate. Despite no effect of bicarbonate at the initial ΔGATP, sequential elevations in 
ΔGATP (i.e. stepwise increase in ATP/ADP) revealed a dose-dependent increase in 
respiratory flux only in mitochondria exposed to bicarbonate (Figure 1A,B). To further 
investigate the influence of bicarbonate on BCKA flux, KIV-supported respiration was 
assessed in response to bicarbonate titration. These experiments were performed using either 
the CK clamp set to the highest ΔGATP (−14.84 kcal/mol) or a hexokinase–ADP clamp 
which maintains free ADP at 0.5 mM without allowing for appreciable ATP [26]. While the 
addition of bicarbonate dose-dependently increased KIV-supported JO2 with the CK clamp, 
this effect was completely absent from the hexokinase-clamp condition (Figure 1C,D), 
presumably due to insufficient ATP-free energy. Importantly, the addition of bicarbonate up 
to 2 mM did not impact buffer pH.
It should be noted that the CK clamp merely maintains extramitochondrial ΔGATP. As such, 
equilibration of ATP-free energy between the buffer and mitochondrial matrix requires a 
functioning phosphorylation system. To determine if matrix ATP-free energy is required for 
maximal BCKA flux, additional experiments were carried out in which buffer ΔGATP was 
set to −14.84 kcal/mol (i.e. 21 mM PCR) and KMV-supported respiration was assessed 
under conditions in which ATP synthesis was compromised with either oligomycin or FCCP. 
Although oligomycin blocks proton conductance (i.e. respiratory flux), FCCP uncouples 
electron transport from ATP synthesis, thus allowing for maximal KMV-dependent flux to 
be determined in the absence of matrix ATP-free energy. Under control conditions, KMV 
once again induced a robust increase in JO2 (Figure 1E). Remarkably, KMV-supported 
respiration was nearly eliminated in mitochondria pre-incubated with FCCP, identical with 
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that seen with oligomycin (Figure 1E). Taken together, these experiments provide 
biochemical evidence that BCKA flux in cardiac mitochondria requires bicarbonate and is 
responsive to matrix ATP-free energy.
BCKA catabolism in cardiac mitochondria minimally contributes to total respiratory 
capacity
Upon establishing the CK clamp with either 1 mM (−12.94 kcal/mol) or 21 mM (−14.84 
kcal/mol) PCR, creatine, and ATP are largely held constant (~5 mM), while free ADP levels 
drop by an order of magnitude (Figure 1F). In traditional respirometry with saturating 
carbon substrates, a 10-fold drop in ADP would be expected to lower respiratory flux 
[16,20,21]. This was indeed the case when isolated heart mitochondria were energized with 
saturating carbon substrates (pyruvate/malate/glutamate/succinate/octanoyl-carnitine; 
P/M/G/S/O; 5/2/5/5/0.2 mM) and assessed at ATP-free energies of −12.94 kcal/mol versus 
−14.84 kcal/mol (Figure 1G; ‘Multi’). Absolute JO2 was subsequently normalized upon the 
addition of FCCP (Figure 1G; ‘FCCP’), confirming that the respiratory differences between 
ΔGATP conditions were caused by a decrease in demand for ATP resynthesis. The traditional 
relationship between ATP-free energy and JO2 is reversed upon energization with KMV 
alone (Figure 1G; ‘KMV’). These data imply that respiratory control in the presence of 
KMV resides entirely with reducing equivalent supply. Thus, maximal respiration supported 
by KMV must be below the threshold at which respiration rate begins to respond linearly to 
free [ADP]. Indeed, when maximal respiration between P/M/G/S/O and KMV-energized 
mitochondria were compared, KMV-supported flux represented only ~3% of P/M/G/S/O 
flux (Figure 1H). Consistent with this, KMV alone, as compared with Pyr/M, was unable to 
a promote measurable reduction in the mitochondrial NAD+ pool or generate a membrane 
potential (ΔΨ) above that observed in mitochondria devoid of exogenous carbon 
(Supplementary Figure S2A–C). Increasing the mitochondrial concentration from 0.1 mg/ml 
to 1 mg/ml was required to observe KMV-supported NAD reduction (Supplementary Figure 
S2D,E). Using heart mitochondria at 1 mg/ml, KMV-supported increases in NAD(P)H/
NAD(P)+ redox state were unaffected by ΔGATP (Supplementary Figure S2F), suggesting 
that the increase in KMV-supported JO2 in response to ΔGATP is not caused by accelerated 
KMV uptake across the inner mitochondrial membrane and/or BCKDH activation.
Dehydrogenase profiling in permeabilized heart mitochondria corroborated the respirometry 
findings as BCKDH flux was found to represent ~2% of maximal NAD-linked capacity 
(Figure 1I). Respirometry analysis and dehydrogenase profiling agree with a recent report 
demonstrating that BCKA contribution to the TCA cycle is <1% in mouse heart [19]. 
Together, these data indicate that the BCKA oxidation pathway minimally contributes to 
maximal catabolic flux in mouse heart.
The inclusion of bicarbonate and ATP permit full BCKA oxidation to either acetyl-CoA or 
succinyl-CoA
Having established that bicarbonate and ATP are required for KMV oxidation, the impact of 
bicarbonate was next assessed in cardiac mitochondria energized with P/M/G/S/O or the 
BCKA corresponding to valine (KIV) or leucine (KIC) metabolism. Although bicarbonate 
did not impact respiratory sensitivity in the presence of P/M/G/S/O (Figure 2A), KIV-
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supported JO2 was dose-dependently increased across the ΔGATP range (Figure 2B), similar 
to KMV-supported respiration (Figure 1B). Interestingly, KIC only marginally increased JO2 
above that of mitochondria alone and was unresponsive to ΔGATP (Figure 2C). KIC 
oxidation produces acetyl-CoA exclusively, raising the possibility that acetyl-CoA build up 
could be inhibiting KIC-supported respiration, similar to pyruvate-supported JO2 [27]. To 
test this hypothesis, KIC-supported JO2 was assessed in the presence of high carnitine or 
following pre-treatment with malate. The presence of excess carnitine provides a substrate 
for carnitine acetyltransferase (CrAT), thus relieving acetyl-CoA-mediated control of 
respiration [27,28]. Malate relieves acetyl-CoA buildup by serving as a source of 
oxaloacetate (acetyl-CoA condenses with oxaloacetate to form citrate). The presence of both 
carnitine and malate increased KIC-supported respiratory flux in a bicarbonate-dependent 
manner (Figure 2D). These findings confirm that in the presence of bicarbonate and ATP-
free energy, in vitro metabolism of KIC is constrained through accumulation of its TCA 
cycle end product, acetyl-CoA.
Oxidation of KIV produces succinyl-CoA exclusively, whereas KMV oxidation can produce 
either acetyl-CoA or succinyl-CoA (Figure 1). To determine if the combination of 
bicarbonate and ATP-free energy permits complete metabolism of KMV to succinyl-CoA, 
KMV-supported JO2 was assessed under high ΔGATP followed by the addition of the 
complex I inhibitor rotenone or the succinate dehydrogenase (SDH) inhibitor malonate. Both 
rotenone and malonate eliminated KMV-dependent flux (Figure 2E,F). Importantly, JO2 was 
restored following the addition of 1 mM succinate only in the plus rotenone condition, thus 
confirming SDH inhibition by malonate (Figure 2F; ‘Succ’). Malonate did not impact 
respiration supported by KIC in heart or liver mitochondria (Supplementary Figure S3A,B). 
Complete inhibition of KMV-dependent flux by malonate confirms that KMV metabolism 
under the experimental conditions employed herein proceeds at least to the level of 
succinate. Metabolite exchange with buffer phosphate across the inner mitochondrial 
membrane could restrict dehydrogenase activity downstream of SDH.
Mitochondrial BCKA oxidation contributes to electron leak
Given that BCKDH is a known source of mitochondrial superoxide [29], experiments were 
designed to assess the peroxide emitting potential of the BCKA oxidation pathway. 
Mitochondrial H2O2 emission was determined in isolated cardiac mitochondria exposed to 
bicarbonate and energized with either KMV or P/M/G/S/O across a span of ΔGATP (−12.94, 
−14.08, −14.84 kcal/mol). Antimycin A was included at the end of the protocol as a positive 
control for H2O2 emission. Although absolute H2O2 emission was lower in the presence of 
KMV compared with P/M/G/S/O (Figure 2G), normalization to the corresponding 
respiration rates (i.e. JH2O2/JO2 = % electron leak) revealed percent electron leak to be 10-
fold higher in KMV-energized mitochondria (Figure 2H). Interestingly, % electron leak 
supported by KMV decreased by ~3-fold across the ΔGATP span, suggesting that electron 
leak is minimal when BCKA catabolism is maximal (Figure 2G; compare ‘KMV’ mean at 
−12.94 vs. −14.84 kcal/mol). Potential sources of electron leak within the BCKA oxidation 
pathway include BCKDH, electron transfer flavoprotein (ETF), and ETF dehydrogenase 
(ETFDH) [30].
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In vivo inhibition of the branched-chain dehydrogenase kinase does not impact maximal 
BCKA oxidation in heart mitochondria
Recent in vivo analysis of BCKA oxidation in mouse heart suggested that maximal BCKA 
flux is constrained in unstressed C57BL/6J mice via inhibitory phosphorylation of BCKDH 
[19]. To determine if inhibitory phosphorylation of BCKDH limits KMV-supported 
respiration, short-term fasted C57BL/6J mice were injected with the BCKDH kinase 
inhibitor BT2 [18,19] (40 mg/kg) or vehicle control. Mice were euthanized 1 h post-
injection and isolated mitochondria were prepared from heart tissue (Figure 3A). 
Assessment of BCKDH activity in permeabilized mitochondria revealed a ~2-fold increase 
in JNADH in mitochondria prepared from BT2-treated mice, consistent with inhibition of 
BCKDH kinase in vivo (Figure 3B,C). Importantly, this increase in JNADH in response to 
KMV was specific to BCKDH, as no differences were observed in pyruvate dehydrogenase 
(PDH) flux (Figure 3C). Despite the evidence of BCKDH activation in vivo, KMV-
supported respiration in heart mitochondria was completely unaffected by BT2 treatment 
(Figure 3D). These data imply that the phosphorylation status of BCKDH is reversible in 
intact isolated organelles, likely through exposure to high BCKA concentrations and/or 
physiological ATP-free energy [31,32]. Moreover, the increase in JO2 in response to 
increasing ΔGATP cannot be explained by gradual BCKDH dephosphorylation.
Tissue-specific differences in mitochondrial BCKA oxidation
To investigate BCKA oxidation across tissues, mitochondria were isolated from skeletal 
muscle and liver of C57BL/6J mice. Respiration supported by KMV was dependent on ATP-
free energy and bicarbonate in skeletal muscle mitochondria, similar to that seen in cardiac 
mitochondria (Figure 4A). In liver mitochondria, bicarbonate once again increased 
respiration supported by each of the three BCKAs (KMV, Figure 4B; KIV, Figure 4C; KIC, 
Figure 4D) as well as the combination of malate and KIC (Figure 4E), consistent with 
bicarbonate being required for maximal BCKA flux in vitro. The inclusion of bicarbonate 
did not impact respiratory sensitivity in the presence of P/M/G/S/O (Figure 4F).
Except for a small increase in KIC-supported JO2 between ΔGATP of −12.94 and −14.08 
kcal/mol (Figure 4E), increasing ATP-free energy via PCR titration induced a drop in 
BCKA-supported respiration in liver mitochondria. These findings differ from those 
observed in heart and skeletal muscle and suggest that BCKA oxidation in liver 
mitochondria is sufficient to support respiratory control. Consistent with this, KMV-
supported respiration was calculated to represent ~18% of maximal respiratory flux in liver 
mitochondria (Figure 4G), considerably higher than that observed in cardiac mitochondria 
(Figure 1H). Dehydrogenase profiling of permeabilized liver mitochondria demonstrated 
that BCKDH flux represents ~7% of maximal NAD flux (Figure 4H). Observed differences 
in BCKA respiratory flux across heart, skeletal muscle, and liver mitochondria are entirely 
consistent with prior metabolic studies implicating hepatocyte metabolism in whole-body 
BCKA homeostasis [33–35].
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Mitochondrial BCKA oxidation specifically lowers glutamate- and α-ketoglutarate (AKG)-
supported respiratory control
Alterations in BCKA oxidation have been linked to numerous human diseases ranging from 
diabetes [3] to cancer [5]. In addition, recent work has linked defective BCKA oxidation in 
cardiac mitochondria to heart failure [6] and ischemia–reperfusion injury [7]. In both cases, 
in vitro experiments determined that BCKAs impaired mitochondrial respiration, reportedly 
via specific inhibition of pyruvate utilization [7]. Given that these previous studies did not 
assess BCKA-induced shifts in JO2 in the context of bicarbonate and physiological ATP-free 
energy, it was hypothesized that BCKAs may differentially impact respiratory control across 
ATP/ADP energetic demands. To test this, isolated heart mitochondria were exposed to 
BCKAs (KIC/KIV/KMV, 1 mM each) or vehicle control (NaCl) and interrogated using a 
recently described mitochondrial diagnostic workflow [16]. In this system, mitochondrial 
JO2 and the corresponding free energies controlling flux (ΔΨ and NAD(P)H/NAD(P)+ 
redox state) are assayed in parallel across a span of ATP-free energies. These experiments 
were conducted in the presence of various substrate combinations (pyruvate/malate, Pyr/M; 
octanoyl-carnitine/malate, Oct/M; glutamate/malate, G/M; succinate/rotenone, S/R; and 
AKG), each of which activates a unique subset of mitochondrial dehydrogenases and 
respiratory complexes. Potassium bicarbonate was present for all experiments. Compared 
with control, mitochondrial respiration was slightly elevated in the presence of BCKAs prior 
to the addition of each substrate combination (Figure 5A; ‘mt’), consistent with BCKA 
oxidation. Although BCKAs did not influence S/R-supported respiratory flux, all NAD-
linked substrate combinations were partially lower in the presence of BCKAs at the lowest 
ATP-free energy, as well as in response to FCCP addition (Figure 5A; ‘−12.94 kcal/mol’ and 
‘FCCP’). Interestingly, respiratory sensitivity calculated from the linear change in JO2 for a 
given ΔGATP shift (−14.08 to −14.84 kcal/mol) revealed BCKA-induced impairments 
exclusively for G/M and AKG energized mitochondria (Figure 5D). These data suggest that 
although high BCKA concentrations generally impinge on maximal NAD-linked flux, 
respiratory impacts across physiological ΔGATP induced by BCKAs are more pronounced 
with respect to glutamate/AKG metabolism.
Parallel measurements of membrane potential (ΔΨ) and NAD(P)H/NAD(P)+ redox state 
allow for differences in respiratory control to be localized into one of three distinct energy 
transduction control nodes: (1) ‘ATP Synthesis’, (2) Electron Transport System (‘ETS’), and 
(3) ‘Matrix Dehydrogenases’. Although ΔΨ was largely unaffected by BCKAs, slight 
depolarization was evident in the presence of both Pyr/M and Oct/M at ΔGATP of −12.94 
kcal/mol (Figure 5B). Membrane potential depolarization was accompanied by NAD(P)H/
NAD(P)+ oxidation across all substrate combinations (Figure 5C), consistent with the source 
of respiratory resistance induced by BCKAs being localized to the matrix dehydrogenases. 
To validate this potential mechanism, dehydrogenase activity was directly assessed in 
permeabilized heart mitochondria exposed to identical BCKA concentrations as those used 
for the respirometry experiments. While slight inhibition was evident for both NADP-linked 
isocitrate dehydrogenase (IDH2) and NAD-linked PDH, both GDH and AKGDH were 
starkly inhibited by BCKAs (Figure 5E). Taken together, these findings provide biochemical 
evidence that under physiological energy constraints BCKAs impinge on AKG/glutamate 
oxidation within heart mitochondria, primarily via inhibition of AKGDH and GDH (Figure 
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6). Such findings agree well with previous reports demonstrating specific inhibition of 
AKGDH by BCKAs [36].
Discussion
As an alternative to tracer analysis [19] and/or RNA sequencing [5], experiments in isolated 
mitochondria represent a powerful model system for comprehensively interrogating BCKA 
flux. That said, only a handful of studies have attempted to measure BCKA-supported 
respiration in isolated organelles [6,7,13–15]. In the majority of cases, BCKA-supported JO2 
was not definitively demonstrated to be higher than that supported by mitochondria alone or 
mitochondria plus malate. Moreover, evidence for respiratory control (i.e. a change in JO2 in 
response to a change in free [ADP]) in the presence of BCKAs was lacking. This difficulty 
likely originated from omission of bicarbonate from the experimental media, as well as the 
use of bolus ADP, rather than physiological ATP/ADP, as the stimulus for increasing 
respiratory flux. Given that full BCKA oxidation requires bicarbonate and ATP, it was 
hypothesized that the inclusion of potassium bicarbonate in the respiratory buffer in 
conjunction with physiological ATP-free energy would stimulate maximal BCKA-supported 
JO2 in isolated mitochondria. This was indeed found to be the case across three murine 
organs (e.g. heart, liver, skeletal muscle). The contributions of BCKA oxidation to total 
respiratory capacity as well as the sensitivity to ΔGATP were found to be distinct across 
tissues. Remarkably, although flux was minimal at low ATP/ADP, BCKA-supported 
respiration in heart and skeletal muscle mitochondria increased over 3-fold across a 
physiological ΔGATP span. This increase in JO2 cannot be explained by ΔGATP-dependent 
changes in BCKA uptake across the inner mitochondrial membrane (Supplementary Figure 
S2F) or activation of BCKDH (Figure 3A–D). Collectivity, these data imply that in addition 
to post-translation control of BCKDH (i.e. phosphorylation) [17], BCKA oxidation in 
muscle mitochondria is exquisitely responsive to matrix ATP-free energy.
Mammalian mitochondria can receive reducing equivalents from each of the three canonical 
macronutrients: carbohydrates (e.g. glucose-derived pyruvate), fatty acids (activated to fatty 
acyl-CoA), and amino acids (e.g. BCKAs). Unlike pyruvate and acyl-CoA, BCKA oxidation 
encompasses an ATP-dependent reaction. In the case of KMV and KIV, this reaction 
involves the ATP/bicarbonate-dependent conversion of propionyl-CoA to D-methylmalonyl-
CoA via propionyl-CoA carboxylase. A similar reaction occurs in the KIC oxidation 
pathway where methylcrotonyl-CoA is converted to methylglutaconyl-CoA. Aside from 
extreme nutrient deprivation (e.g. extreme endurance exercise and/or starvation), 
mitochondrial respiratory flux is principally governed by the intracellular demand for ATP 
regeneration. That is, any drop in ΔGATP is counter-balanced by reciprocal activation of 
catabolic flux (e.g. TCA cycle and β-oxidation) that increases respiration to restore ATP-free 
energy. The responsivity of these catabolic pathways to ΔGATP is largely mediated by NAD-
linked dehydrogenases that are exquisitely sensitive to NADH/NAD+ redox balance. In the 
present study, BCKA-supported respiration in murine mammalian mitochondria, particularly 
from skeletal muscle and heart, was found to be highly responsive to increasing ΔGATP. 
These data provide biochemical evidence that maximal BCKA oxidation in peripheral 
tissues may occur under conditions of high BCKA availability and low energetic demand 
(i.e. fed state conditions). In support of this notion, recent in vivo flux analysis demonstrated 
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increased BCKA contribution to the TCA cycle pool in skeletal muscle and heart in response 
to physiologic hyperinsulinemia [19]. Indeed, previous findings suggest that the primary 
function of BCKA oxidation in muscle involves anaplerotic replenishment of TCA cycle 
intermediates to support β-oxidation flux [37]. Additional investigation is required to 
elucidate if ATP-free energy is indeed rate-limiting for BCKA catabolism in vivo, 
particularly with respect to KIV and KMV oxidation.
Compared with muscle, BCKA oxidation in liver mitochondria was far less sensitive to both 
exogenous bicarbonate and ΔGATP. Given that bicarbonate is produced during BCKA 
decarboxylation, it is possible that higher BCKDH catalytic flux in liver mitochondria 
provides an endogenous source of matrix-localized bicarbonate to fuel sub-maximal BCKA 
oxidation. Across the three tissues interrogated, liver mitochondria were the only tissue in 
which BCKA-mediated respiratory control was observed. These data imply that in contrast 
with muscle mitochondria, the BCKA oxidation pathway in liver can substantially contribute 
to overall hepatic energy production. In support of this, whole-body BCKA homeostasis is 
restored in MSUD patients following hepatic transplantation [35].
Multiple reports exist linking increased mitochondrial BCKA exposure to impaired 
mitochondrial respiration [6,7,14,15]. Importantly, these studies did not assess BCKA-
induced shifts in JO2 in the context of bicarbonate and physiological ATP-free energy, nor 
were the inhibitory effects of BCKAs assessed across multiple substrate combinations. The 
present study leveraged a recently described mitochondrial diagnostics workflow to 
unbiasedly assess the impact of BCKAs on cardiac mitochondrial respiratory control [16]. 
Exposure to BCKAs generally depressed maximal JO2 for all NAD-linked substrate 
combinations. Parallel determinations of ΔΨ and NAD(P) H/NAD(P)+ redox localized the 
source of BCKA-induced inhibition to the matrix dehydrogenases. Interestingly, respiratory 
sensitivity across a physiological span of ΔGATP was depressed by BCKAs only in the 
presence of G/M and AKG. Direct interrogation of dehydrogenase flux corroborated the 
respirometry data, evident by pronounced inhibition of both AKGDH and GDH by BCKAs. 
Although previous studies have documented BCKA-induced inhibition of AKGDH [15,36], 
loss of GDH activity may be mediated via BCKA-dependent competition with BCAA 
aminotransferase (BCAT) and/or reductive amination of exogenous BCKAs by GDH 
directly [38]. With respect to AKGDH inhibition, previous work has demonstrated that KIC 
is more potent than KMV or KIV [15]. Taken together, these findings suggest that the 
primary bioenergetic consequences of compromised BCKA metabolism likely involve 
limitations in AKG and/or glutamate metabolism.
In aggregate, the current study provides a framework for comprehensive interrogation of 
BCKA metabolism in isolated mitochondria. To illustrate the utility of this novel 
methodology, consider that a recent report demonstrated using RNA sequencing that several 
common laboratory mouse strains carry mild inborn errors of metabolism within the BCKA 
oxidation pathway [39]. Leveraging the assays described herein, straightforward 
experiments could easily be designed and carried out to validate the functional impact of 
these inborn errors across organs. Of course, similar methodologies could also be applied to 
elucidate the functional impact of stress and disease on BCKA metabolism, a critical open 
question across multiple disciplines.
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MSUD maple syrup urine disease
PCR phosphocreatine
PDH pyruvate dehydrogenase complex
SDH succinate dehydrogenase
TMRM tetramethylrhodamine methyl ester
ΔGATP ATP-free energy of hydrolysis
ΔΨ mitochondrial membrane potential
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Figure 1. Overview of BCKA oxidation.
BCAA/BCKA catabolic pathway resulting in TCA cycle intermediates. Complete oxidation 
of all three BCKAs in isolated mitochondria requires a carboxylase reaction. This reaction is 
either carried out by methylcrotonyl-CoA carboxylase (KIC; reaction indicated by ‘1’ in the 
figure) or propionyl-CoA carboxylase (KMV and KIV; reaction indicated by ‘2’ in the 
figure). Both enzymes are biotin-dependent enzymes that use bicarbonate to catalyze 
carboxylation in an ATP-dependent reaction. Unlike biotin, which is bound to the matrix 
enzymes, both ATP and bicarbonate are depleted from the mitochondrial matrix during the 
isolation procedure.
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Figure 2. BCKA oxidation in heart mitochondria requires both bicarbonate and physiological 
ATP-free energy of hydrolysis.
Isolated heart mitochondria were used for all experiments. (A) Representative trace of JO2 
during a phosphocreatine (PCR) titration in the absence and presence of 2 mM bicarbonate. 
(B) Quantification of data from (A) depicting the relationship between JO2 and ΔGATP in 
mitochondria energized with KMV in the presence and absence of bicarbonate. Rates to the 
left of the dotted line correspond to mitochondria alone (‘mt’). (C) Representative trace of 
JO2 during a bicarbonate titration in the presence of the CK or hexokinase clamp. (D) JO2 
quantification of the bicarbonate titration from the data depicted in (C). (E) Mitochondrial 
JO2 without exogenous carbon substrates or saturating KMV in the absence and presence of 
either FCCP (2 μM) or oligomycin (Oligo; 2 μM). (F) Calculated changed in ATP, ADP, 
PCR, and Cr at different ΔGATP (−12.94 kcal/mol vs. −14.84 kcal/mol). (G) Heart 
mitochondria incubated at ΔGATP of −12.94 kcal/mol versus. −14.84 kcal/mol and energized 
with P/M/G/S/O (5/2/5/5/0.2 mM; ‘Multi’), P/M/G/S/O plus FCCP (2 μM; ‘FCCP’) or 
KMV alone (‘KMV’). (H) Comparison of KMV-supported respiration versus maximal 
respiratory flux (G compare ‘FCCP’ to ‘KMV’ at ΔGATP of −14.84 kcal/mol). (I) 
Dehydrogenase profiling in permeabilized cardiac mitochondria. BCKDH is highlighted in 
the red filled circle. Data are expressed as Log2 JNADH/JNADPH. Data are mean ± SEM, n 
= 3–7/group, *P < 0.05, **P < 0.001, ***P < 0.0001.
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Figure 3. Detailed characterization of BCKA metabolism in cardiac mitochondria.
Isolated heart mitochondria were used for all experiments. All bicarbonate conditions were 
done in the presence of 2 mM bicarbonate. (A) Relationship between mitochondrial oxygen 
consumption and ATP-free energy in heart mitochondria energized with P/M/G/S/O. Rates 
to the left of the dotted line correspond to mitochondria alone (‘mt’). (B,C) Relationship 
between mitochondrial oxygen consumption and ATP-free energy in the presence of (B) 
KIV or (C) KIC. Rates to the left of the dotted line correspond to mitochondria alone (‘mt’). 
(D) Mitochondrial ΔGATP was set to −14.84 kcal/mol and JO2 was assessed under the 
following substrate combinations: mitochondria alone (‘mt’), KIC (‘mt/KIC’), KIC plus 5 
mM carnitine (‘mt/KIC/Carn’), malate (‘mt/Mal’) and malate plus KIC (‘mt/Mal/KIC’). (E) 
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Representative JO2 trace depicting KMV-supported flux followed by the sequential additions 
of either rotenone (5 μM) or malonate (‘Malo’; 5 mM) and then succinate (1 mM). Of note, 
mitochondrial ΔGATP was set to −14.84 kcal/mol and bicarbonate was present during the 
experiment. (F) JO2 quantification of the experiment in (E). (G) H2O2 production in heart 
mitochondria in the presence of either KMV or P/M/G/S/O assessed at various ATP-free 
energies. Antimycin A (5 μM) was added at the end of the protocol to serve as a positive 
control. (H) Relationship between electron leak (% Leak = JH2O2/JO2) and ΔGATP for both 
substrate conditions. Data are mean ± SEM, n = 3–4/group, *P < 0.05, **P < 0.001.
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Figure 4. Inhibition of BCKDH kinase in vivo does not impact maximal BCKA-supported 
mitochondrial respiration.
(A) Schematic of experimental timeline with BT2. (B) Representative fluorescent trace 
depicting KMV-supported JNADH in alamethicin-permeabilized heart mitochondria from 
mice treated with DMSO or BT2. (C) Quantification of BCKDH and PDH activity from 
heart mitochondria of mice treated with DMSO or BT2. Data are expressed as a percentage 
of activity from DMSO-treated mice. (D) Relationship between JO2 and ΔGATP for KMV-
energized heart mitochondria from DMSO and BT2-treated mice. Rates to the left of the 
dotted line correspond to mitochondria alone (‘mt’). Data are mean ± SEM, n = 4/group, *P 
< 0.05.
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Figure 5. Comparison of BCKA oxidation in skeletal muscle versus liver mitochondria.
(A–F) Experiments were performed in the presence and absence of bicarbonate (2 mM). (A) 
Relationship between mitochondrial oxygen consumption and ATP-free energy in skeletal 
muscle mitochondria energized with KMV. Rates to the left of the dotted line correspond to 
mitochondria alone (‘mt’). (B–D) Relationship between mitochondrial oxygen consumption 
and ATP-free energy in liver mitochondria energized with (B) KMV, (C) KIV, or (D) KIC. 
Rates to the left of the dotted line correspond to mitochondria alone (‘mt’). (E) JO2 upon 
energization of liver mitochondria with malate and KIC across a span of ATP-free energies. 
Sequential PCRs in the figure correspond to final concentrations of 6, 9, 15, and 21 mM. (F) 
Relationship between mitochondrial oxygen consumption and ATP-free energy in liver 
mitochondria energized with P/M/G/S/O. Rates to the left of the dotted line correspond to 
mitochondria alone (‘mt’). (G) Comparison of the average maximal KMV-supported 
respiration in liver mitochondria versus the average maximal respiratory flux supported by 
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P/M/G/S/O. (H) Dehydrogenase profiling in permeabilized liver mitochondria. BCKDH is 
highlighted in the green filled circle. Data are expressed as Log2 JNADH/JNADPH. Data 
are mean ± SEM, n = 4/group, *P < 0.05.
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Figure 6. Comprehensive assessment of heart mitochondrial respiratory control in the presence 
of BCKAs.
All experiments were performed in isolated heart mitochondria in the presence of either 
NaCl (3 mM) or a BCKA mixture (1 mM:1 mM:1 mM of KIC/KMV/KIV). (A) 
Relationship between JO2 and ATP-free energy in mitochondria energized with differing 
substrates (Pyr/M, Oct/M, G/M, S/R, AKG). Rates to the left of the first dotted line 
correspond to mitochondria alone (‘mt’). Rates to the right of the second dotted line 
represent JO2 following the addition of FCCP (2 μM) at the end of the PCR titration 
(‘FCCP’). (B) Relationship between mitochondrial membrane potential (ΔΨ) and ATP-free 
energy in mitochondria energized with varying substrates (Pyr/M, Oct/M, G/M, S/R). Values 
to the left of the first dotted line correspond to mitochondria alone (‘mt’). Values to the right 
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of the second dotted line represent ΔΨ following the addition of oligomycin (‘Oligo’; 5 μM) 
and cyanide (‘CN’; 10 mM) at the end of the PCR titration. (C) Relationship between 
NAD(P)H/NAD(P)+ redox and ATP-free energy under the same conditions as in (B). (D) 
Respiratory sensitivity for each substrate combination determined from the linear change in 
JO2 as a function of ΔGATP (−14.08 kcal/mol to −14.84 kcal/mol). (E) Dehydrogenase 
activity in permeabilized heart mitochondria exposed to NaCl or BCKAs. Data are expressed 
as a percentage of the average NaCl rate for each enzyme. Data are mean ± SEM, n = 6–8/
group. *P < 0.05, **P < 0.001, ***P < 0.0001.
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Figure 7. Summary diagnostics of BCKA-mediated shifts in heart respiratory control.
Diagnostic tree diagram depicting the primary bioenergetic mechanism by which BCKAs 
lower heart mitochondrial respiration. Starting with loss of respiratory flux or sensitivity, 
potential primary mechanisms are depicted in the dark grey-filled ovals (‘ATP synthesis’, 
‘ETS’) with the BCKA-specific mechanism indicated in red (‘Matrix Dehydrogenases’). 
The experimental evidence in support of a ‘Matrix Dehydrogenases’ mechanism is provided 
in the ‘Diagnostic Report’ box.
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